Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00059972" target="_blank" >RIV/00216224:14110/12:00059972 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/12:8038 RIV/00064203:_____/12:8038

Výsledek na webu

<a href="http://dx.doi.org/10.1016/S1470-2045(11)70299-6" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(11)70299-6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S1470-2045(11)70299-6" target="_blank" >10.1016/S1470-2045(11)70299-6</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

Popis výsledku v původním jazyce

The risk of recurrence of gastrointestinal stromal tumour (GIST) after surgery needs to be estimated when considering adjuvant systemic therapy. We assessed prognostic factors of patients with operable GIST, to compare widely used risk-stratification schemes and to develop a new method for risk estimation. Methods Population-based cohorts of patients diagnosed with operable GIST, who were not given adjuvant therapy, were identified from the literature. Data from ten series and 2560 patients were pooled.Risk of tumour recurrence was stratified using the National Institute of Health (NIH) consensus criteria, the modified consensus criteria, and the Armed Forces Institute of Pathology (AFIP) criteria. Prognostic factors were examined using proportional hazards and non-linear models. The results were validated in an independent centre-based cohort consisting of 920 patients with GIST. Findings Estimated 15-year recurrence-free survival (RFS) after surgery was 59.9% (95% CI 56.2-63.

Název v anglickém jazyce

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

Popis výsledku anglicky

The risk of recurrence of gastrointestinal stromal tumour (GIST) after surgery needs to be estimated when considering adjuvant systemic therapy. We assessed prognostic factors of patients with operable GIST, to compare widely used risk-stratification schemes and to develop a new method for risk estimation. Methods Population-based cohorts of patients diagnosed with operable GIST, who were not given adjuvant therapy, were identified from the literature. Data from ten series and 2560 patients were pooled.Risk of tumour recurrence was stratified using the National Institute of Health (NIH) consensus criteria, the modified consensus criteria, and the Armed Forces Institute of Pathology (AFIP) criteria. Prognostic factors were examined using proportional hazards and non-linear models. The results were validated in an independent centre-based cohort consisting of 920 patients with GIST. Findings Estimated 15-year recurrence-free survival (RFS) after surgery was 59.9% (95% CI 56.2-63.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Lancet Oncology

ISSN

1470-2045

e-ISSN

—

Svazek periodika

13

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

265-274

Kód UT WoS článku

000300880600034

EID výsledku v databázi Scopus

—